Sanofi and GSK launch trials of Covid-19 vaccine

FoodCloud CEO wins European Tech Women Award

Prodigy Learning wins contract for evaluation tool in Irish schools

Why Facebook can simply block Australian users from sharing news

Zoom Exceeds Maximum Expectations With 355% Profit Expansion

Independent investigators to investigate Facebook in elections

“There are wonderful opportunities in the fitness box now, but it’s a tough time for start-ups”

Apple, Google unveil more highlights over latest touch tracking update

Facebook and Twitter delete Russian-linked accounts from US users.But it’s not the first time

Cybercriminals mimic key logo spaces to defraud customers

The Covid Tracker Ireland app has been updated.What is it?

Workday’s CIO: “Covid-19 has replaced paintings of us overnight”

8.3 million Freepik users exposed in recent knowledge gaps

What about Google and Facebook underwater cable packages?

Eir fiber broadband reaches 2 million installations

Virgin Media switches to 1 Gbps broadband on Irish network

Local government calls for 5G national strategy

Huawei says 5G ban is ‘bad news for uk cell phoners’

ComReg: part of Irish respondents willing to pay more for more broadband

Startup Boost launches for its Irish pre-accelerator’s programs

SoftBank leads $100 million at Biofourmis

6 proptech startups to watch

Zipp Mobility invests 500,000 euros from Brian O’Driscoll and others

Patreon secures a $ 90 million investment to turn it into a unicorn

Cork corporations team up for ‘next generation of software entrepreneurs’

To take the weekend: back with 10 wonderful science and technology readings

Moral license in the world of design

Countdown to the Irish scientific extravaganza Inspirefest 2017

Time to get Inspirefest Early Bird tickets is up

Construction begins on the € 500 million Limerick Twenty Thirty

Dave, the generation and power of people

UCD and TCD studies to benefit from CKD start-up grants

Sanofi and GSK release trials of Covid-19 vaccine

Astronomers stumble upon a bang never noticed between two black holes

How’s er in “what if?” Have you led to a career in cybersecurity?

RCSI receives a grant of 420,000 euros for Covid-19

An uns married Covid-19 vaccine can be effective against all existing strains

The new Irish Centre for Intensive Computing is presented as an EU initiative

“People of color have the power to make the adjustments they make”

ESB receives a loan of 150 million euros for national counter deployment

Elon Musk’s first step towards ‘superhuman cognition’ in a pig’s brain

Eco-friendly adhesive with sticky bare fly legs

U.S. to create 12 centers for artificial intelligence and quantum research

How many more people can live on Earth?

Forget the weather for centuries, more like decades, say climate scientists

WeForest doubles its crowdfunding purpose to empower an Indian village

The world awaits the birth of ‘baby dragons’ in Slovenia

Discovery of gold and platinum in the streams of south-eastern Ireland

Bees are in trouble, so are we.

The best combination: Inspirefest offers a stimulating combination of STEM and humanity.

Instant Inspirefest: Prodigy has an empire builder for women in STEM

Vogue 25 celebrates science, social media and activism

With dreams of making in space, this woman is a real inspiration.

Girls4Tech and STEM for everyone in the coolest projects

The Storytellers: 12 shine in STEM

8 Ways to Bring Your Brand To Life By Hiring Remotely

Answer: five questions about Covid-19 workers’ travel

“Resilience is anything you were born with, it’s a skill you learn”

5 Things Leaders Should Consider for the New Era of Work

What do you want in your long-term toolbox?

7 skills sought through long-term recruiters

How this architect can make a difference in fitness care

How Kelly McConville of N26 handled her imposter syndrome

Because ‘there’s always something new and attractive to learn’ as a knowledge scientist

16 long-term influencers of the task you follow

PwC’s Sinéad Thavenot: “We all want an expansion mentality and continuous skill improvement”

“Gone are the days of uncompromising, unproductive and climate-prone travel.”

6 leading corporations recruiting lately on the data

How do corporations see the diversity of their workforce?

6 lately recruiting in fintech

7 United States is recruiting lately in Ireland

7 of the world’s coolest scientific papers

Do you have a career in marketing? An analytical brain is useful

US company Peak6 announces 160 new jobs in Belfast

Regeneron to upload new jobs to Limerick pharmaceutical base

20 new “long-term” jobs at MSD Ballydine

Thermo Fisher Scientific to 36 ‘high-level’ jobs in Cork

What skills do you want to teach a robot in a genomics lab?

7 are hiring in sunny south-eastern Ireland

Could you confidentially report symptoms and return to paints safely?

Covid requests robotic procedure automation skills, according to survey

German union calls for four-day weeks of Covid task cuts

Improves the 15 highest-paid programming languages on your website

Could a virtual reality viewer look remotely?

Employees longer while running from home, according to a survey

Why ‘catch nettles’ will go to companies after Covid-19

Join us for Future Human, the first primary hybrid generation event

What will Irish paintings look like in a post-Covid world?

How Enterprise Ireland supports start-ups in the face of a pandemic

“We’re running into that that’s never been resolved before”

How can you thrive in a post-Covid world?

If existing clinical trials are successful, Sanofi and GSK plan to launch Phase 3 trials until the end of the year, which could allow them to seek regulatory approval for a vaccine in the early part of 2021.

Pharmaceutical giants GSK and Sanofi have begun one and two clinical trials for their Covid-19 adjuvant vaccine.

The candidate vaccine developed through either corporation uses the same generation of recombinant protein as one of Sanofi’s existing seasonal influenza vaccines, as well as the generation of adjuvants from GSK. Adjuvants are pharmacological or immunological responsive agents. immune to a vaccine.

This clinical trial is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability and immune reaction of the Covid-19 vaccine candidate.A total of 440 healthy adults enrolled in the trial at 11 sites in the United States..

Companies expect the first effects in December 2020, which will mean launching a Phase 3 test until the end of the year if everything goes according to plan. If knowledge is sufficient for a license application, GSK and Sanofi aim to seek approval regulations in the first part of 2021.

Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur’s Commercial Vaccine Division, Sanofi Pasteur, said: “Sanofi and GSK are bringing proven science and generation to combat the global Covid-19 pandemic, with the unusual purpose of offering a vaccine.

“The publication of our clinical examination is a vital step and brings us closer to a possible vaccine that could defeat the Covid-19.Our committed groups and partners continue to work 24 hours a day, as our goal is to achieve the first effects in early December.Positive knowledge will allow the fundamental Phase 3 test to begin temporarily until the end of this year.”

Roger Connor, president of GSK Vaccines, added: “The transition from this candidate vaccine to clinical progression is a time in progress in addressing the global pandemic we all face.

“This is based on the trust already demonstrated through governments in the potential of this adjuvant protein vaccine, which uses the established generation of any of the corporations and can be produced on a giant scale.”

The Covid-19 adjuvant candidate vaccine is supported through investment and collaboration with the Advanced Biomedical Research and Development Authority in the United States.

Sanofi and GSK have announced in the past their purpose of offering one hundred million doses of the Covid-19 vaccine to the United States, while the United States budgets up to $2.1 billion for development, clinical trials, and manufacturing.

According to a regulatory opinion reported through Reuters, China has presented experimental coronavirus vaccines to aviation industry personnel in an effort to inoculate high-risk equipment into a new wave of cases as economies reopen.

Reuters reported that China has 4 Covid-19 vaccines at the highest level of human trials and now gives experimental vaccines to teams such as border inspectors and medical industry personnel who may be exposed to increased exposure due to their work.program in July.

The Chinese Civil Administration has reportedly asked corporations in these sectors to draw up a list of staff willing to receive the experimental vaccine, in addition to China’s airlines, airports, and National Aviation Fuel Group.

Elsewhere, a study published this week warned that there is limited diversity in the new coronavirus, SARS-CoV-2, meaning that a single Covid-19 vaccine can be effective against all known strains.

Our online site uses cookies for your experience.Visit our Privacy Policy page to learn more about cookies and how we use them.

Leave a Comment

Your email address will not be published. Required fields are marked *